ID
31385
Beskrivning
Study ID: 104507 Clinical Study ID: BEX104507 Study Title: Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996593 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin
Nyckelord
Versioner (2)
- 2018-08-06 2018-08-06 -
- 2018-08-18 2018-08-18 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
18 augusti 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphomas NCT00996593
Independent Response Evaluation Oncologist's Assessment and Consensus Criteria
Beskrivning
Consensus Criteria
Alias
- UMLS CUI-1
- C0376298
- UMLS CUI-2
- C0243161
Beskrivning
Response to treatment; Date in time
Datatyp
date
Alias
- UMLS CUI [1,1]
- C0521982
- UMLS CUI [1,2]
- C0011008
Beskrivning
Consensus; Response to treatment
Datatyp
text
Alias
- UMLS CUI [1,1]
- C0376298
- UMLS CUI [1,2]
- C0521982
Beskrivning
Comments
Datatyp
text
Alias
- UMLS CUI [1]
- C0947611
Beskrivning
Administrative
Alias
- UMLS CUI-1
- C1320722
Similar models
Independent Response Evaluation Oncologist's Assessment and Consensus Criteria
C0011008 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0521982 (UMLS CUI [1,2])
C1519316 (UMLS CUI [1,2])
Inga kommentarer